NCT05276687

Brief Summary

  1. 1.Infection control and health-care-associated infections and Safety of medical service providers
  2. 2.Evidence based management of common medical and surgical problems

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 11, 2022

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

March 11, 2022

Status Verified

March 1, 2022

Enrollment Period

1.5 years

First QC Date

March 3, 2022

Last Update Submit

March 10, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Superficial wound infection

    Within 20 days

  • Deep wound infection

    Within 20 days

Secondary Outcomes (1)

  • Healing of sternum ( within 2 months)

    20 days to 60 days

Study Arms (3)

Diluted betadine

EXPERIMENTAL
Drug: Betadine

Powdered vancomycin

EXPERIMENTAL
Drug: Vancomycin

No intervention

NO INTERVENTION

Interventions

Wound irrigation

Diluted betadine

instillation in the wound

Powdered vancomycin

Eligibility Criteria

Age1 Year - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • age from 1 to 65 years, primary or redo cases

You may not qualify if:

  • diabetic patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Cotogni P, Barbero C, Rinaldi M. Deep sternal wound infection after cardiac surgery: Evidences and controversies. World J Crit Care Med. 2015 Nov 4;4(4):265-73. doi: 10.5492/wjccm.v4.i4.265. eCollection 2015 Nov 4.

    PMID: 26557476BACKGROUND
  • Singh K, Anderson E, Harper JG. Overview and management of sternal wound infection. Semin Plast Surg. 2011 Feb;25(1):25-33. doi: 10.1055/s-0031-1275168.

    PMID: 22294940BACKGROUND
  • Kotnis-Gaska A, Mazur P, Olechowska-Jarzab A, Stanisz A, Bulanda M, Undas A. Sternal wound infections following cardiac surgery and their management: a single-centre study from the years 2016-2017. Kardiochir Torakochirurgia Pol. 2018 Jun;15(2):79-85. doi: 10.5114/kitp.2018.76472. Epub 2018 Jun 25.

    PMID: 30069187BACKGROUND
  • Asghar A, Talha KM, Amanullah M, Shahabuddin S. Comparison of figure of eight and traditional simple wire closure method to prevent dehiscence after sternal closure. J Pak Med Assoc. 2020 Nov;70(11):2001-2006. doi: 10.5455/JPMA.20135.

    PMID: 33341848BACKGROUND
  • Goswami K, Austin MS. Intraoperative povidone-iodine irrigation for infection prevention. Arthroplast Today. 2019 May 22;5(3):306-308. doi: 10.1016/j.artd.2019.04.004. eCollection 2019 Sep.

    PMID: 31516971BACKGROUND

MeSH Terms

Conditions

Surgical Wound Infection

Interventions

Povidone-IodineVancomycin

Condition Hierarchy (Ancestors)

Wound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

IodophorsIodine CompoundsInorganic ChemicalsPolyvinylsVinyl CompoundsAlkenesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsPovidonePyrrolidinonesPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPlasticsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgricultureGlycopeptidesGlycoconjugatesCarbohydratesPeptidesAmino Acids, Peptides, and Proteins

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

March 3, 2022

First Posted

March 11, 2022

Study Start

September 1, 2022

Primary Completion

March 1, 2024

Study Completion

April 1, 2024

Last Updated

March 11, 2022

Record last verified: 2022-03